Abstracts tagged "psoriatic arthritis and tumor necrosis factor (TNF)"

Abstract Number: 841 • 2018 ACR/ARHP Annual Meeting
TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways
Unnikrishnan M Chandrasekharan¹, Jennifer Harvey², Vandana Rai³, Chad Braley⁴, MacKenzie Lee³, Jason Hsieh³, Ritika Jaini⁵, Anthony Fernandez⁶, Paul DiCorleto⁷ and M. Elaine Husni⁸, ¹Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH, ²Department of Cellular and Molecular, Cleveland Clinic, Cleveland, OH, ³Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Department of Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Dermatology and Pathology, Cleveland Clinic, Cleveland, OH, ⁷Division of Research and Sponsored Programs, Kent State, kent, OH, ⁸Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH
Background/Purpose: Tumor necrosis factor-a (TNF), a potent proinflammatory cytokine, activates two receptors: TNFR1 and TNFR2. Anti-TNF biological agents neutralize TNF, thus preventing both TNFR1 and…
Abstract Number: 2615 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Handan Yarkan¹, Gokce Kenar¹, Sedat Capar², Gerçek Can¹, Berrin Zengin¹, Servet Akar³, Ediz Dalkiliç⁴, Soner Senel⁵, Suleyman Serdar Koca⁶, Abdurrahman Tufan⁷, Ayten Yazici⁸, Nevsun İnanç⁹, Hülya Ellidokuz¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Statistics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁵Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁶Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁷Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁸Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁹Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, ¹⁰Statistics, Dokuz Eylül Üniversity Faculty of Medicine, IZMIR, Turkey, ¹¹Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: The aim of the study was to investigate the impact of smoking on disease activity, treatment adherence and treatment response in psoriatic arthritis (PsA)…
Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Josef S. Smolen¹, Philip J Mease², Christopher T. Ritchlin³, Tore K Kvien⁴, Luminita Pricop⁵, Todd Fox⁶, Lawrence Rasouliyan⁷, Steffen Jugl⁶ and Corine Gaillez⁶, ¹Medical University of Vienna, Vienna, Austria, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…
Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Mahdi Gharaibeh¹, Yingxin Xu², Joseph Lee³, Madhura Chitnis² and David Collier⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Evidera, Bethesda, MD, ³videra, Bethesda, MD, ⁴Amgen, Inc, Terni, Italy
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…
Abstract Number: 958 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Philip J Mease¹, Mark C. Genovese², Michael Weinblatt³, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Heikki T. Mansikka⁴, Amit Khatri⁴, Ahmed A. Othman⁴, Neil Wishart⁴, John Liu⁴ and Robert J. Padley⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Stanford University Medical Center, Palo Alto, CA, ³Brigham and Women’s Hospital, Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…
Abstract Number: 1301 • 2016 ACR/ARHP Annual Meeting
Analysis of Anatomical Sites Causing Dactylitis and Their Responsiveness to Change Under TNF-Therapy in Psoriatic Arthritis By High Resolution MRI
Dr. Philipp Sewerin, PD Dr. Stefan Vordenbäumen, Dr. Ruben Sengewein, Prof. Dr. Matthias Schneider and Prof. Dr. Benedikt Ostendorf, Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Results: The following sites were most commonly involved in dactylitis: collateral ligament enthesitis 11/12 (92%); extensor tendons enthesitis 5/12 (42%); flexor tenosynovitis 9/12 (75%),…
Abstract Number: 1668 • 2016 ACR/ARHP Annual Meeting
Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models
Unnikrishnan Chandrasekharan¹, Chad Braley², Jennifer Harvey³, Zeneng Wang¹, Paul DiCorleto⁴ and M. Elaine Husni⁵, ¹Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH, ²Department of Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, ³Department of Cellular and Molecular, Cleveland Clinic, Cleveland, OH, ⁴Division of Research and Sponsored Programs, Kent State, kent, OH, ⁵Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Tumor necrosis factor-α (TNF) activates two receptors globally, TNFR1 and TNFR2. Neutralizing antibodies or soluble TNF receptors can inactivate TNF, blocking activity of both…
Abstract Number: 2883 • 2015 ACR/ARHP Annual Meeting
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Laure Gossec¹, Tore K. Kvien², Philip G. Conaghan³, Mikkel Østergaard⁴, Juan D. Cañete⁵, C. Gaillez⁶, Shephard Mpofu⁶, Bintu Sherif⁷ and Steffen Jugl⁸, ¹Rheumatology Department, Paris 06 University,Hôpital Pitié Salpêtrière, Paris, France, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Durham, NC, ⁸BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Fatigue is highly important to patients (pts) with psoriatic arthritis (PsA). Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved the signs and symptoms of active…
Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Doquyen H. Huynh¹, Carol J. Etzel^2,3, Vanessa Cox⁴, Philip J. Mease⁵ and Arthur Kavanaugh⁶, ¹Rheumatology, UC San Diego School of Medicine, San Diego, CA, ²PO Box 786, Corrona, LLC., Southborough, MA, ³Department of Epidemiology, UT MD Anderson, Houston, TX, ⁴CORRONA, Inc, Southborough, MA, ⁵CORRONA, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
Abstract Number: 305 • 2013 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Devy Zisman^1,2, Haim Bitterman^1,3, Ilan Feldhamer⁴, Doron Comanesther⁴, Erez Battat⁴, Sari Greenberg-Dotan⁴, Sarit Cohen⁵ and Arnon-Dov Cohen⁴, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Chief Physician's Office, Clalit Health Services, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Medical Center, Haifa, Israel
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…
Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Bente Glintborg^1,2, Bjorn Gudbjornsson^3,4, Niels Steen Krogh⁵, Emina Omerovic², Natalia Manilo⁶, Mette Holland-Fischer⁷, Hanne M. Lindegaard⁸, Anne Gitte Loft⁹, Henrik Nordin¹⁰, Laura Johnsen¹¹, Sussi Flejsborg Oeftiger¹², Annette Hansen¹³, Claus Rasmussen¹⁴, Gerdur Grondal¹⁵, Árni Jón Geirsson¹⁶ and Merete Lund Hetland^1,2,17, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ¹⁰Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹¹Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, ¹²Department of Rheumatology, Køge Hospital, Køge, East Timor, ¹³Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ¹⁴Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹⁵Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Amir Haddad¹, Arane Thavaneswaran¹, Ioana Ruiz Arruza², Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…
Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Glenn Haugeberg¹, Andreas P. Diamantopoulos¹, Agnete Gulati², Mari Hoff³ and Arthur Kavanaugh⁴, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, St.Olavs Hospital, Trondheim, Norway, ³Rheumatology, St Olavs Hospital, Trondheim, Norway, ⁴University of California San Diego, San Diego, CA
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…
Abstract Number: 2582 • 2012 ACR/ARHP Annual Meeting
Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Stephanie Finzel¹, Sebastian Kraus¹, Sarah Schmidt¹, Axel J. Hueber², Juergen Rech³, Klaus Engelke⁴, Matthias Englbrecht¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To investigate whether methotrexate (MTX) or tumour necrosis factor inhibition (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with…
Abstract Number: 2231 • 2012 ACR/ARHP Annual Meeting
Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: 2 Year Results of a Prospective Cohort Study
Leonard C. Harty¹, Alex Franciosi², Naomi Pettysan², Paul Rushe² and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Treatment resistant psoriatic arthritis (PsA) may render a patient unwell, disabled and incapable of work with previous reports suggesting that unemployment levels among PsA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].